HUT65353A - Process for producing pharmaceutical preparations containing antiaritmyc, analgetic and multi-drog-resistance breaking through phtalazinon derivatives - Google Patents

Process for producing pharmaceutical preparations containing antiaritmyc, analgetic and multi-drog-resistance breaking through phtalazinon derivatives Download PDF

Info

Publication number
HUT65353A
HUT65353A HU9302784A HU9302784A HUT65353A HU T65353 A HUT65353 A HU T65353A HU 9302784 A HU9302784 A HU 9302784A HU 9302784 A HU9302784 A HU 9302784A HU T65353 A HUT65353 A HU T65353A
Authority
HU
Hungary
Prior art keywords
medicament
manufacture
compound
formula
treatment
Prior art date
Application number
HU9302784A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9302784D0 (en
Inventor
Juergen Engel
Ilona Fleischhauer
Bernhard Kutscher
Ulrich Werner
Peter Metzenauer
Stefan Szelenyi
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of HU9302784D0 publication Critical patent/HU9302784D0/hu
Publication of HUT65353A publication Critical patent/HUT65353A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HU9302784A 1992-10-02 1993-10-01 Process for producing pharmaceutical preparations containing antiaritmyc, analgetic and multi-drog-resistance breaking through phtalazinon derivatives HUT65353A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4233113 1992-10-02

Publications (2)

Publication Number Publication Date
HU9302784D0 HU9302784D0 (en) 1993-12-28
HUT65353A true HUT65353A (en) 1994-05-02

Family

ID=6469448

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9302784A HUT65353A (en) 1992-10-02 1993-10-01 Process for producing pharmaceutical preparations containing antiaritmyc, analgetic and multi-drog-resistance breaking through phtalazinon derivatives

Country Status (18)

Country Link
US (1) US5556856A (enExample)
EP (1) EP0590551B1 (enExample)
JP (1) JP3623975B2 (enExample)
CN (1) CN1088435A (enExample)
AT (1) ATE144708T1 (enExample)
AU (1) AU666773B2 (enExample)
CA (1) CA2107548A1 (enExample)
CZ (1) CZ199593A3 (enExample)
DE (1) DE59304351D1 (enExample)
DK (1) DK0590551T3 (enExample)
ES (1) ES2096168T3 (enExample)
GR (1) GR3022070T3 (enExample)
HU (1) HUT65353A (enExample)
MX (1) MX9306120A (enExample)
RU (1) RU2106143C1 (enExample)
SK (1) SK104493A3 (enExample)
UA (1) UA26953C2 (enExample)
ZA (1) ZA937315B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162616A (en) * 1997-04-16 2000-12-19 Millennium Pharmaceuticals, Inc. Multidrug resistance-associated polypeptide
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2003041128A2 (en) * 2001-11-07 2003-05-15 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20080039444A1 (en) * 2006-04-20 2008-02-14 Glaxo Group Limited Compounds
WO2007144639A1 (en) * 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
US20090181951A1 (en) * 2006-06-15 2009-07-16 Kudos Pharmaceuticals Limited Parp inhibitors
US20090281086A1 (en) * 2006-06-15 2009-11-12 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US20100184770A1 (en) * 2006-12-20 2010-07-22 Glaxo Group Limited Compounds
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
ATE525370T1 (de) * 2007-10-11 2011-10-15 Glaxo Group Ltd Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten
CA2702429A1 (en) 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
CA2737400C (en) * 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
US20110015393A1 (en) * 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2031813T3 (es) * 1985-11-11 1993-01-01 Asta Pharma Ag Procedimiento para la preparacion de derivados de 4-bencil-1-(2h)-ftalazinona.
JPH0667844B2 (ja) * 1987-03-06 1994-08-31 エーザイ株式会社 虚血性心疾患の治療・予防剤
US5110814A (en) * 1989-01-11 1992-05-05 Asta Pharma Ag Azelastine and its salts used to combat psoriasis

Also Published As

Publication number Publication date
AU666773B2 (en) 1996-02-22
RU2106143C1 (ru) 1998-03-10
UA26953C2 (uk) 1999-12-29
US5556856A (en) 1996-09-17
GR3022070T3 (en) 1997-03-31
ZA937315B (en) 1994-04-22
EP0590551A3 (enExample) 1994-08-31
DK0590551T3 (da) 1997-04-21
JPH06312928A (ja) 1994-11-08
SK104493A3 (en) 1994-08-10
CN1088435A (zh) 1994-06-29
DE59304351D1 (de) 1996-12-05
CZ199593A3 (en) 1994-04-13
CA2107548A1 (en) 1994-04-03
ES2096168T3 (es) 1997-03-01
EP0590551B1 (de) 1996-10-30
AU4876993A (en) 1994-04-14
JP3623975B2 (ja) 2005-02-23
HU9302784D0 (en) 1993-12-28
EP0590551A2 (de) 1994-04-06
MX9306120A (es) 1994-04-29
ATE144708T1 (de) 1996-11-15

Similar Documents

Publication Publication Date Title
HUT65353A (en) Process for producing pharmaceutical preparations containing antiaritmyc, analgetic and multi-drog-resistance breaking through phtalazinon derivatives
EP2789617B1 (en) Method of preparation of Enantiomers of spiro-oxindole compounds
Diness et al. The KCa2 channel inhibitor AP30663 selectively increases atrial refractoriness, converts vernakalant-resistant atrial fibrillation and prevents its reinduction in conscious pigs
US20150238473A1 (en) Methods and compositions for treating infection
US20080075666A1 (en) Methods and compositions for treating diastolic dysfunction
CN101969954A (zh) 三芳基甲烷类似物及其在治疗癌症中的用途
JP2021507944A (ja) 運動ニューロン疾患を含む神経障害のための組成物および治療方法
Milberg et al. Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3
EP3697767B1 (en) Compounds and methods for treating cancer
KR20120032476A (ko) 암 치료에 사용하기 위한 방사선감작제로서 피롤리딘-치환된 플라본
KR20240093500A (ko) 암 치료를 위한 엔독시펜
CN109761958A (zh) 法舒地尔复合盐及其制备方法和用途
US5238947A (en) Synthetic piperidinediones with cytostatic activity
KR100545930B1 (ko) 첼리도닌 또는 그 유도체를 포함하는 약제학적 조성물
RU2299210C2 (ru) 3-фенил-3,7-диазабицикло[3,3,1]нонановые соединения, способ их получения и лекарственные средства, содержащие эти соединения
CN121450790B (zh) 检测KCNJ8基因c.263C＞G突变的试剂在制备遗传性心律失常诊断产品中的应用
US4198408A (en) Method for blocking high frequency nerve stimulation
JPH01143855A (ja) 低級アルキルスルフアモイルアミン類、その塩およびその用途
US6476047B2 (en) Anellated dihydropyridines for the treatment of chronic pain
CA3036568C (en) Methods for treating ovarian cancer
JP2019532934A (ja) 卵巣癌を治療するための方法
CN104116740B (zh) 汉防己甲素治疗老年痴呆症的医药用途及含有汉防己甲素的药物组合物
RU1208774C (ru) Дихлоргидрат 9-метил-12- [2-(4-метилпиперазино)этил] -6,7-дигидробенз [2`,3`] оксепино [4,5-b] индола, обладающий антиаритмической активностью
CA2922013C (en) Chemical inducers of fetal hemoglobin
CHINA Putting Smartphones to Good Use: Early Warning Detection Systems for Lung Cancer and Ketosis/Diabetes

Legal Events

Date Code Title Description
DFC4 Cancellation of temporary protection due to refusal